Merck & Co., Inc. Financial Highlights Package Second Quarter 2022 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 2Q22 and June YTD 22.......3 Table 2b: GAAP to Non-GAAP Reconciliation 2Q21 and June YTD 21.......4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / Ex- U.S. 2Q22........................................................6 Table 3b: Sales – U.S. / Ex- U.S. June YTD 22............................................7 Table 3c: Sales – Pharmaceutical Geographic Split....................................8 Table 4: Other (Income) Expense .............................................................9 -- 1 of 10 -- Sales 14,593 $ 11,402 $ 28% 30,494 $ 22,029 $ 38% Costs, Expenses and Other Cost of sales 4,216 3,104 36% 9,596 6,303 52% Selling, general and administrative 2,512 2,281 10% 4,834 4,468 8% Research and development 2,798 4,321 -35% 5,374 6,732 -20% Restructuring costs 142 82 73% 194 380 -49% Other (income) expense, net 438 (103) * 1,148 (558) * Income from Continuing Operations Before Taxes 4,487 1,717 * 9,348 4,704 99% Income Tax Provision 538 503 1,092 741 Net Income from Continuing Operations 3,949 1,214 * 8,256 3,963 * Less: Net Income Attributable to Noncontrolling Interests 5 1 2 5 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,944 1,213 * 8,254 3,958 * Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests - 332 * - 766 * Net Income Attributable to Merck & Co., Inc. 3,944 $ 1,545 $ * 8,254 $ 4,724 $ 75% Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.56 $ 0.48 $ * 3.26 $ 1.56 $ * Income from Discontinued Operations - 0.13 * - 0.30 * Net Income 1.56 $ 0.61 $ * 3.26 $ 1.87 $ 74% Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.55 $ 0.48 $ * 3.25 $ 1.56 $ * Income from Discontinued Operations - 0.13 * - 0.30 * Net Income 1.55 $ 0.61 $ * 3.25 $ 1.86 $ 75% Average Shares Outstanding 2,531 2,533 2,529 2,532 Average Shares Outstanding Assuming Dilution 2,540 2,540 2,538 2,540 Tax Rate from Continuing Operations 12.0% 29.3% 11.7% 15.8% * 100% or greater CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change GAAP % Change 2Q22 On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon). The historical results of the businesses that were contributed to Organon in the spin-off are excluded from sales and expenses and reflected as discontinued operations in the company’s Consolidated Statement of Income provided below. 2Q21 June YTD 2022 June YTD 2021 1 -- 2 of 10 -- Sales 15,901 $ 14,593 $ 30,494 $ 10,627 $ 11,402 $ 22,029 $ 13,154 $ 13,521 $ 48,704 $ 28% 38% Costs, Expenses and Other Cost of sales 5,380 4,216 9,596 3,199 3,104 6,303 3,450 3,873 13,626 36% 52% Selling, general and administrative 2,323 2,512 4,834 2,187 2,281 4,468 2,336 2,830 9,634 10% 8% Research and development 2,576 2,798 5,374 2,412 4,321 6,732 2,445 3,068 12,245 -35% -20% Restructuring costs 53 142 194 297 82 380 107 174 661 73% -49% Other (income) expense, net 708 438 1,148 (455) (103) (558) (450) (333) (1,341) * * Income from Continuing Operations Before Taxes 4,861 4,487 9,348 2,987 1,717 4,704 5,266 3,909 13,879 * 99% Income Tax Provision 554 538 1,092 238 503 741 695 85 1,521 Net Income from Continuing Operations 4,307 3,949 8,256 2,749 1,214 3,963 4,571 3,824 12,358 * * Less: Net (Loss) Income Attributable to Noncontrolling Interests (3) 5 2 4 1 5 4 4 13 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,310 3,944 8,254 2,745 1,213 3,958 4,567 3,820 12,345 * * Income (Loss) from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests - - - 434 332 766 - (62) 704 * * Net Income Attributable to Merck & Co., Inc. 4,310 $ 3,944 $ 8,254 $ 3,179 $ 1,545 $ 4,724 $ 4,567 $ 3,758 $ 13,049 $ * 75% Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.70 $ 1.56 $ 3.26 $ 1.08 $ 0.48 $ 1.56 $ 1.81 $ 1.51 $ 4.88 $ * * Income (Loss) from Discontinued Operations - - - 0.17 0.13 0.30 - (0.02) 0.28 * * Net Income 1.70 $ 1.56 $ 3.26 $ 1.26 $ 0.61 $ 1.87 $ 1.81 $ 1.49 $ 5.16 $ * 74% Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.70 $ 1.55 $ 3.25 $ 1.08 $ 0.48 $ 1.56 $ 1.80 $ 1.51 $ 4.86 $ * * Income (Loss) from Discontinued Operations - - - 0.17 0.13 0.30 - (0.02) 0.28 * * Net Income 1.70 $ 1.55 $ 3.25 $ 1.25 $ 0.61 $ 1.86 $ 1.80 $ 1.48 $ 5.14 $ * 75% Average Shares Outstanding 2,528 2,531 2,529 2,531 2,533 2,532 2,530 2,527 2,530 Average Shares Outstanding Assuming Dilution 2,537 2,540 2,538 2,541 2,540 2,540 2,536 2,535 2,538 Tax Rate from Continuing Operations 11.4% 12.0% 11.7% 8.0% 29.3% 15.8% 13.2% 2.2% 11.0% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. % Change 2Q June YTD June YTD 2022 2Q June YTD 1Q 1Q 2Q 3Q 4Q Full Year 2021 Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) 2 -- 3 of 10 -- Second Quarter Cost of sales 4,216 $ 451 67 518 3,698 $ Selling, general and administrative 2,512 65 27 92 2,420 Research and development 2,798 12 22 34 2,764 Restructuring costs 142 142 142 - Other (income) expense, net 438 2 234 236 202 Income from Continuing Operations Before Taxes 4,487 (530) (258) (234) (1,022) 5,509 Income Tax Provision (Benefit) 538 (131) (3) (40) (3) (52) (3) (223) 761 Net Income from Continuing Operations 3,949 (399) (218) (182) (799) 4,748 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,944 (399) (218) (182) (799) 4,743 Earnings per Common Share Assuming Dilution from Continuing Operations 1.55 $ (0.16) (0.09) (0.07) (0.32) 1.87 $ Tax Rate 12.0% 13.8% June YTD Cost of sales 9,596 $ 1,131 113 1,244 8,352 $ Selling, general and administrative 4,834 115 48 163 4,671 Research and development 5,374 34 29 63 5,311 Restructuring costs 194 - 194 194 - Other (income) expense, net 1,148 (112) 918 806 342 Income from Continuing Operations Before Taxes 9,348 (1,168) (384) (918) (2,470) 11,818 Income Tax Provision (Benefit) 1,092 (286) (3) (62) (3) (204) (3) (552) 1,644 Net Income from Continuing Operations 8,256 (882) (322) (714) (1,918) 10,174 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 8,254 (882) (322) (714) (1,918) 10,172 Earnings per Common Share Assuming Dilution from Continuing Operations 3.25 $ (0.35) (0.13) (0.28) (0.76) 4.01 $ Tax Rate 11.7% 13.9% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2022 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amount included in other (income) expense, net, for the six month period primarily reflects royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal 3 -- 4 of 10 -- Second Quarter Cost of sales 3,104 $ 345 38 37 (3) 420 2,684 $ Selling, general and administrative 2,281 25 2 27 2,254 Research and development 4,321 16 6 22 4,299 Restructuring costs 82 82 82 - Other (income) expense, net (103) 117 (258) (141) 38 Income from Continuing Operations Before Taxes 1,717 (503) (128) 258 (37) (410) 2,127 Income Tax Provision (Benefit) 503 (98) (4) (15) (4) 57 (4) (8) (4) (64) 567 Net Income from Continuing Operations 1,214 (405) (113) 201 (29) (346) 1,560 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 1,213 (405) (113) 201 (29) (346) 1,559 Earnings per Common Share Assuming Dilution from Continuing Operations 0.48 $ (0.16) (0.04) 0.08 (0.01) (0.13) 0.61 $ Tax Rate 29.3% 26.7% June YTD Cost of sales 6,303 $ 842 65 225 (3) 1,132 5,171 $ Selling, general and administrative 4,468 35 4 39 4,429 Research and development 6,732 34 13 47 6,685 Restructuring costs 380 380 380 - Other (income) expense, net (558) 89 (819) (730) 172 Income from Continuing Operations Before Taxes 4,704 (1,000) (462) 819 (225) (868) 5,572 Income Tax Provision (Benefit) 741 (187) (4) (56) (4) 180 (4) (257) (4) (320) 1,061 Net Income from Continuing Operations 3,963 (813) (406) 639 32 (548) 4,511 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,958 (813) (406) 639 32 (548) 4,506 Earnings per Common Share Assuming Dilution from Continuing Operations 1.56 $ (0.32) (0.16) 0.25 0.02 (0.21) 1.77 $ Tax Rate 15.8% 19.0% Only the line items that are affected by non-GAAP adjustments are shown. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non- GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the second quarter and six month period primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture and a loss on a forward exchange contract entered into in conjunction with the Organon spin-off. Amount included in other (income) expense, net, for the six month period was partially offset by royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents charges for the discontinuation of COVID-19 development programs. (4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the six month period also includes a $207 million net tax benefit related to the settlement of certain federal income tax matters. Adjustment Subtotal Non-GAAP MERCK & CO., INC. SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Table 2b In 2022, the company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the charges were considered by the company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Beginning in 2022, Merck’s non-GAAP results no longer exclude charges related to these items. Results for 2021 have been recast to conform to the new presentation. 4 -- 5 of 10 -- 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $15,901 $14,593 $30,494 $10,627 $11,402 $22,029 $13,154 $13,521 $48,704 28 31 38 41 PHARMACEUTICAL 14,107 12,756 26,863 9,238 9,980 19,218 11,496 12,039 42,754 28 33 40 45 Oncology Keytruda 4,809 5,252 10,061 3,899 4,176 8,076 4,534 4,577 17,186 26 30 25 29 Alliance Revenue – Lynparza (2) 266 275 541 228 248 475 246 268 989 11 17 14 18 Alliance Revenue – Lenvima (2) 227 231 459 130 181 310 188 206 704 28 33 48 51 Alliance Revenue – Reblozyl (3) 52 33 86 17 17 * * * * Vaccines (4) Gardasil / Gardasil 9 1,460 1,674 3,133 917 1,234 2,151 1,993 1,528 5,673 36 40 46 48 ProQuad / M-M-R II / Varivax 470 578 1,047 449 516 965 661 509 2,135 12 14 9 10 RotaTeq 216 173 389 158 208 366 227 213 807 -17 -14 6 8 Pneumovax 23 173 153 325 171 152 323 277 292 893 1 4 1 3 Vaqta 36 35 71 34 56 90 48 41 179 -38 -38 -21 -21 Hospital Acute Care Bridion 395 426 821 340 387 727 369 436 1,532 10 15 13 17 Prevymis 94 103 197 82 93 174 96 100 370 11 18 13 19 Primaxin 58 64 122 65 60 125 70 65 259 6 8 -2 -2 Dificid 52 66 119 27 34 61 54 60 175 95 95 95 95 Noxafil 57 60 118 67 66 133 64 62 259 -8 -3 -11 -7 Invanz 52 46 99 57 48 104 53 45 202 -3 1 -5 -2 Cancidas 53 42 95 57 54 111 56 45 212 -23 -20 -15 -13 Zerbaxa 30 46 76 (8) (1) (9) (2) 10 (1) * * * * Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 72 98 170 74 74 149 100 94 342 33 33 14 15 Adempas (6) 61 63 124 55 74 129 59 63 252 -14 -5 -4 6 Virology Lagevrio 3,247 1,177 4,424 952 952 * * * * Isentress / Isentress HD 158 147 305 209 192 401 189 178 769 -24 -19 -24 -20 Neuroscience Belsomra 69 69 137 79 78 157 81 80 318 -12 -2 -13 -5 Immunology Simponi 186 181 366 214 202 416 203 206 825 -10 1 -12 -3 Remicade 61 53 114 85 75 160 73 67 299 -29 -19 -29 -20 Diabetes (7) Januvia 779 756 1,535 809 784 1,593 852 878 3,324 -4 1 -4 - Janumet 454 476 931 486 477 962 487 514 1,964 0 6 -3 2 Other Pharmaceutical (8) 520 479 998 554 512 1,069 518 533 2,118 -6 -3 -7 -3 ANIMAL HEALTH 1,482 1,467 2,949 1,418 1,472 2,890 1,417 1,261 5,568 - 5 2 7 Livestock 832 826 1,658 819 821 1,640 864 791 3,295 1 6 1 7 Companion Animals 650 641 1,291 599 651 1,250 553 470 2,273 -2 3 3 7 Other Revenues (9) 312 370 682 (29) (50) (79) 241 221 382 * * * * * 200% or greater 2022 2021 2Q June YTD (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $1,305 million and $1,300 million in the first and second quarter of 2022, respectively, and $1,363 million, $1,330 million, $1,417 million and $1,475 million in the first, second, third and fourth quarter of 2021, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $114 million and $32 million in the first and second quarter of 2022, respectively, and $56 million, $135 million and $27 million in the first, third and fourth quarter of 2021, respectively. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment. (4) Total Vaccines sales were $2,481 million and $2,709 million in the first and second quarter of 2022, respectively, and $1,809 million, $2,293 million, $3,315 million and $2,715 million in the first, second, third and fourth quarter of 2021, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 5 -- 6 of 10 -- 2Q 2022 2Q 2021 % Change 2Q 2022 2Q 2021 % Change 2Q 2022 2Q 2021 % Change TOTAL SALES (1) $14,593 $11,402 28 $6,238 $5,100 22 $8,355 $6,301 33 PHARMACEUTICAL 12,756 9,980 28 5,726 4,647 23 7,030 5,333 32 Oncology Keytruda 5,252 4,176 26 3,197 2,347 36 2,055 1,829 12 Alliance Revenue - Lynparza (2) 275 248 11 143 124 15 132 124 7 Alliance Revenue - Lenvima (2) 231 181 28 128 88 46 103 93 11 Alliance Revenue - Reblozyl (3) 33 * 28 * 5 * Vaccines (4) Gardasil / Gardasil 9 1,674 1,234 36 428 454 -6 1,245 781 60 ProQuad / M-M-R II / Varivax 578 516 12 434 386 13 143 130 10 RotaTeq 173 208 -17 98 111 -11 75 97 -23 Pneumovax 23 153 152 1 94 100 -6 59 52 14 Vaqta 35 56 -38 16 22 -27 19 34 -45 Hospital Acute Care Bridion 426 387 10 237 197 20 190 190 - Prevymis 103 93 11 47 37 28 56 56 - Dificid 66 34 95 63 32 100 3 2 30 Primaxin 64 60 6 174 64 60 6 Noxafil 60 66 -8 16 14 11 45 52 -14 Zerbaxa 46 (1) * 22 (2) * 24 1 * Invanz 46 48 -3 2 (4) -139 45 52 -13 Cancidas 42 54 -23 2 1 * 39 53 -26 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 98 74 33 88 81 9 10 (7) * Adempas (6) 63 74 -14 63 74 -14 Virology Lagevrio 1,177 * * 1,177 * Isentress / Isentress HD 147 192 -24 67 74 -10 80 118 -32 Neuroscience Belsomra 69 78 -12 19 14 34 50 63 -22 Immunology Simponi 181 202 -10 181 202 -10 Remicade 53 75 -29 53 75 -29 Diabetes (7) Januvia 756 784 -4 301 284 6 455 500 -9 Janumet 476 477 - 105 74 43 371 403 -8 Other Pharmaceutical (8) 479 512 -6 191 213 -10 288 299 -4 ANIMAL HEALTH 1,467 1,472 - 477 459 4 990 1,012 -2 Livestock 826 821 1 164 161 2 662 659 - Companion Animals 641 651 -2 313 298 5 328 353 -7 Other Revenues (9) 370 (50) * 35 (6) * 335 (44) * * 200% or greater Sum of U.S. plus international may not equal global due to rounding. Table 3a MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS SECOND QUARTER 2022 (AMOUNTS IN MILLIONS) (UNAUDITED) (9) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues related to the receipt of milestone payments for out-licensed products were $32 million in the second quarter of 2022. Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,709 million in the second quarter of 2022 and $2,293 million in the second quarter of 2021. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $1,300 million in the second quarter of 2022 and $1,330 million in the second quarter of 2021. (8) Includes Pharmaceutical products not individually shown above. 6 -- 7 of 10 -- June YTD 2022 June YTD 2021 % Change June YTD 2022 June YTD 2021 % Change June YTD 2022 June YTD 2021 % Change TOTAL SALES (1) $30,494 $22,029 38 $13,577 $9,890 37 $16,917 $12,139 39 PHARMACEUTICAL 26,863 19,218 40 12,498 8,941 40 14,364 10,277 40 Oncology Keytruda 10,061 8,076 25 5,976 4,528 32 4,085 3,548 15 Alliance Revenue - Lynparza (2) 541 475 14 283 242 17 257 233 10 Alliance Revenue - Lenvima (2) 459 310 48 284 173 64 175 137 27 Alliance Revenue - Reblozyl (3) 86 * 55 * 30 * Vaccines (4) Gardasil / Gardasil 9 3,133 2,151 46 846 766 10 2,287 1,385 65 ProQuad / M-M-R II / Varivax 1,047 965 9 805 718 12 243 246 -2 RotaTeq 389 366 6 273 229 19 116 137 -16 Pneumovax 23 325 323 1 212 173 22 114 150 -24 Vaqta 71 90 -21 45 47 -4 25 43 -40 Hospital Acute Care Bridion 821 727 13 432 364 19 389 363 7 Prevymis 197 174 13 87 72 21 110 103 7 Primaxin 122 125 -2 1 * 122 125 -2 Dificid 119 61 95 113 56 100 6 4 38 Noxafil 118 133 -11 25 29 -13 92 104 -11 Invanz 99 104 -5 2 * 96 104 -7 Cancidas 95 111 -15 4 3 15 91 108 -16 Zerbaxa 76 (9) * 40 (4) * 36 (5) * Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 170 149 14 159 149 7 11 * Adempas (6) 124 129 -4 124 129 -4 Virology Lagevrio 4,424 * 1,523 * 2,901 * Isentress / Isentress HD 305 401 -24 128 145 -12 177 256 -31 Neuroscience Belsomra 137 157 -13 39 32 22 98 125 -22 Immunology Simponi 366 416 -12 366 416 -12 Remicade 114 160 -29 114 160 -29 Diabetes (7) Januvia 1,535 1,593 -4 626 632 -1 909 961 -5 Janumet 931 962 -3 168 158 7 762 805 -5 Other Pharmaceutical (8) 998 1,069 -7 372 429 -13 628 640 -2 ANIMAL HEALTH 2,949 2,890 2 951 896 6 1,998 1,994 - Livestock 1,658 1,640 1 335 318 6 1,322 1,322 - Companion Animals 1,291 1,250 3 616 578 7 676 672 - Other Revenues (9) 682 (79) * 128 53 142 555 (132) * * 200% or greater Sum of U.S. plus international may not equal global due to rounding. Table 3b Global U.S. International MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS JUNE YEAR-TO-DATE 2022 (AMOUNTS IN MILLIONS) (UNAUDITED) (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $146 million and $56 million on a global basis for June YTD 2022 and 2021, respectively. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment. (4) Total Vaccines sales were $5,191 million and $4,102 million on a global basis for June YTD 2022 and 2021, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $2,605 million and $2,693 million on a global basis for June YTD 2022 and 2021, respectively. (1) Only select products are shown. 7 -- 8 of 10 -- TOTAL PHARMACEUTICAL $14,107 $12,756 $26,863 $9,238 $9,980 $19,218 $11,496 $12,039 $42,754 28 40 United States 6,773 5,726 12,499 4,294 4,647 8,941 5,670 5,790 20,401 23 40 % Pharmaceutical Sales 48.0% 44.9% 46.5% 46.5% 46.6% 46.5% 49.3% 48.1% 47.7% Europe (1) 3,309 2,677 5,986 2,276 2,404 4,680 2,445 2,655 9,780 11 28 % Pharmaceutical Sales 23.5% 21.0% 22.3% 24.6% 24.1% 24.4% 21.3% 22.1% 22.9% China 1,113 1,355 2,468 688 944 1,632 1,278 1,352 4,262 44 51 % Pharmaceutical Sales 7.9% 10.6% 9.2% 7.4% 9.5% 8.5% 11.1% 11.2% 10.0% Japan 965 1,092 2,057 607 637 1,244 614 771 2,629 71 65 % Pharmaceutical Sales 6.8% 8.6% 7.7% 6.6% 6.4% 6.5% 5.3% 6.4% 6.1% Asia Pacific (other than China and Japan) 786 854 1,640 437 442 879 450 488 1,817 93 87 % Pharmaceutical Sales 5.6% 6.7% 6.1% 4.7% 4.4% 4.6% 3.9% 4.1% 4.2% Latin America 435 453 888 353 379 732 434 421 1,587 20 21 % Pharmaceutical Sales 3.1% 3.6% 3.3% 3.8% 3.8% 3.8% 3.8% 3.5% 3.7% Eastern Europe/Middle East/Africa 450 339 789 357 318 675 362 278 1,315 7 17 % Pharmaceutical Sales 3.2% 2.7% 2.9% 3.9% 3.2% 3.5% 3.1% 2.3% 3.1% Canada 189 166 354 160 157 318 164 167 650 5 12 % Pharmaceutical Sales 1.3% 1.3% 1.3% 1.7% 1.6% 1.7% 1.4% 1.4% 1.5% Other 87 94 182 66 52 117 79 117 313 81 56 % Pharmaceutical Sales 0.6% 0.6% 0.7% 0.8% 0.4% 0.5% 0.8% 0.9% 0.8% 2022 2021 % Change MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c June YTD Sum of quarterly amounts may not equal year-to-date amounts due to rounding. 1Q 2Q June YTD 1Q 2Q June YTD (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 3Q 4Q Full Year 2Q 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 2Q22 2Q21 June YTD 2022 June YTD 2021 Interest income (15) $ (9) $ (22) $ (20) $ Interest expense 240 202 483 401 Exchange losses 86 114 124 155 Loss (income) from investments in equity securities, net (1) 284 (280) 991 (854) Net periodic defined benefit plan (credit) cost other than service cost (27) (110) (148) (199) Other, net (130) (20) (280) (41) Total 438 $ (103) $ 1,148 $ (558) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --